Moderna, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips

AI-generated analysis

📉 Moderna stock dropped 18% to $142.70 on Thursday as investors unwound a massive 177% rally following a Phase 3 cancer vaccine win.

✅ The intismeran trial showed meaningful reduction in melanoma recurrence when combined with Merck's Keytruda, validating years of Phase 2 signals.

📊 JPMorgan analyst Jessica Fye stated that success in adjuvant melanoma was already priced in before the news broke.

💡 Bank of America analyst Alec Stranahan called the result a watershed moment enabling diversification away from infectious disease.

⏳ The full dataset required for complete validation is scheduled to be presented at the ESMO conference in Madrid in late October.

🔬 Moderna now holds a credible oncology franchise on top of its existing infectious-disease business base.

📈 Moderna's market cap was approximately $56.18 billion, significantly larger than Merck's incremental gain from the same trial data.

Bullish Signals
  • The Phase 3 trial for intismeran showed a meaningful reduction in melanoma recurrence when paired with Keytruda, validating years of Phase 2 signals.
  • Bank of America analyst Alec Stranahan described the result as a watershed moment that effectively allows the company to diversify away from infectious disease.
  • The successful trial validates the read-across potential for Moderna's mRNA oncology platform, establishing a credible new franchise.
Risk Factors
  • JPMorgan analyst Jessica Fye noted that success in adjuvant melanoma was already priced in with the stock sitting at ~$25bn market cap prior to the news.
  • The unresolved question of whether the melanoma result reads across to other tumor types remains open until the full dataset is presented publicly.
  • Citigroup analyst Geoff Meacham cautioned that full validation depends on the complete dataset, potentially due at the ESMO conference in late October.
Full Analysis
Moderna (MRNA) shares fell 18% to $142.70 on Thursday, reversing a historic 177% rally from Wednesday following the announcement of a Phase 3 win for its personalized cancer vaccine, intismeran. The trial demonstrated a meaningful reduction in melanoma recurrence when paired with Merck's Keytruda, validating previous signals and establishing a credible oncology franchise alongside Moderna's infectious disease portfolio. Analysts offered mixed reactions to the data readout. JPMorgan noted that success in adjuvant melanoma was largely priced in prior to the news, citing a market cap of approximately $25 billion before the announcement. Conversely, Bank of America viewed the result as a watershed moment that could allow Moderna to diversify away from infectious diseases and potentially ease persistent capital overhangs. The stock's volatility highlights the market's sensitivity to read-across potential for other tumor types, as the full dataset is not yet public. The next major catalyst is expected at the ESMO conference in Madrid in late October, where the complete data will be presented to confirm or complicate the bull case for Moderna's oncology platform.